EU's CHMP OKs paediatric indication for BMS's Reyataz
This article was originally published in Scrip
Executive Summary
The EU's CHMP has endorsed a wider label for Bristol-Myers Squibb's oral HIV protease inhibitor Reyataz (atazanavir sulphate), for use in paediatric patients who are older than six years of age.